These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 36179990)
1. External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis. Patel SA; Ma TM; Wong JK; Stish BJ; Dess RT; Pilar A; Reddy C; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Tran PT; Krauss DJ; Abu-Isa EI; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; DeWeese TL; Tilki D; Ciezki JP; Karnes RJ; Nickols NG; Rettig MB; Feng FY; Berlin A; Tward JD; Davis BJ; Reiter RE; Boutros PC; Romero T; Horwitz EM; Tendulkar RD; Steinberg ML; Spratt DE; Xiang M; Kishan AU Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):645-653. PubMed ID: 36179990 [TBL] [Abstract][Full Text] [Related]
2. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort. Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241 [TBL] [Abstract][Full Text] [Related]
3. Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer. Fischer-Valuck BW; Rao YJ; Brenneman RJ; Patel PR; Filson CP; Jani AB; Liu Y; Goyal S; Xu K; Weiss A; Kucuk O; Cimmino C; Szabo S; Rossi P; Baumann BC; Pattaras J; Hershatter B; Patel SA Brachytherapy; 2020; 19(5):557-566. PubMed ID: 32624405 [TBL] [Abstract][Full Text] [Related]
4. Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. Kishan AU; Karnes RJ; Romero T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Braccioforte M; Huland H; Tran PT; Martin S; Martínez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Chang AJ; Pisansky TM; Choo R; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; D'Amico AV; Rettig MB; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D JAMA Netw Open; 2021 Jul; 4(7):e2115312. PubMed ID: 34196715 [TBL] [Abstract][Full Text] [Related]
5. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254 [TBL] [Abstract][Full Text] [Related]
6. Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy. Andruska N; Agabalogun T; Fischer-Valuck BW; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Carmona R; Baumann BC Brachytherapy; 2022; 21(5):617-625. PubMed ID: 35641370 [TBL] [Abstract][Full Text] [Related]
7. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865 [TBL] [Abstract][Full Text] [Related]
8. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. Kishan AU; Steigler A; Denham JW; Zapatero A; Guerrero A; Joseph D; Maldonado X; Wong JK; Stish BJ; Dess RT; Pilar A; Reddy C; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Tilki D; Karnes RJ; Tosoian JJ; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Jiang T; Ma TM; Xiang M; Philipson R; Chang A; Kupelian PA; Rettig MB; Feng FY; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Boutros PC; Horwitz EM; Tendulkar RD; Spratt DE; Romero T JAMA Oncol; 2022 Mar; 8(3):e216871. PubMed ID: 35050303 [TBL] [Abstract][Full Text] [Related]
9. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy. Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132 [TBL] [Abstract][Full Text] [Related]
10. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. King MT; Chen MH; Moran BJ; Braccioforte MH; Buzurovic I; Muralidhar V; Yang DD; Mouw KW; Devlin PM; D'Amico AV; Nguyen PL; Orio PF Urol Oncol; 2018 Apr; 36(4):157.e15-157.e20. PubMed ID: 29276060 [TBL] [Abstract][Full Text] [Related]
11. Assessing the role of external beam radiation therapy in combination with brachytherapy versus brachytherapy alone for unfavorable intermediate-risk prostate cancer. Andruska N; Michalski JM; Carmona R; Agabalogun T; Brenneman RJ; Gay HA; Fischer-Valuck BW; Baumann BC Brachytherapy; 2022; 21(3):317-324. PubMed ID: 35123889 [TBL] [Abstract][Full Text] [Related]
12. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study. Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887 [TBL] [Abstract][Full Text] [Related]
13. The risk of death from prostate cancer in men with Gleason score 3+4 prostate cancer treated using brachytherapy with or without a short course of androgen deprivation therapy. Yang DD; Chen MH; Wu J; Braccioforte MH; Moran BJ; D'Amico AV Urol Oncol; 2022 Jan; 40(1):6.e21-6.e27. PubMed ID: 34315661 [TBL] [Abstract][Full Text] [Related]
14. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. Yang DD; Muralidhar V; Mahal BA; Nguyen PL; Devlin PM; King MT; Orio PF Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):53-58. PubMed ID: 29254781 [TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Kishan AU; Shaikh T; Wang PC; Reiter RE; Said J; Raghavan G; Nickols NG; Aronson WJ; Sadeghi A; Kamrava M; Demanes DJ; Steinberg ML; Horwitz EM; Kupelian PA; King CR Eur Urol; 2017 May; 71(5):766-773. PubMed ID: 27452951 [TBL] [Abstract][Full Text] [Related]
16. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. Jackson WC; Hartman HE; Dess RT; Birer SR; Soni PD; Hearn JWD; Reichert ZR; Kishan AU; Mahal BA; Zumsteg ZS; Efstathiou JA; Kaffenberger S; Morgan TM; Mehra R; Showalter TN; Krauss DA; Nguyen PL; Schipper MJ; Feng FY; Sandler HM; Hoskin PJ; Roach M; Spratt DE J Clin Oncol; 2020 Sep; 38(26):3024-3031. PubMed ID: 32396488 [TBL] [Abstract][Full Text] [Related]
17. Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. Yang DD; Muralidhar V; Nguyen PL; Buzurovic I; Martin NE; Mouw KW; Devlin PM; Trinh QD; Orio PF; King MT Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):904-911. PubMed ID: 29063853 [TBL] [Abstract][Full Text] [Related]
18. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa). Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838 [TBL] [Abstract][Full Text] [Related]